About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024Reviewers 2026
ISSN 0300-9092 (Print)
ISSN 2412-5679 (Online)
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024Reviewers 2026
Logout
Obstetrics and Gynegology2026№10

New trends in breast cancer screening. The effect of epigenetic therapy on breast tissue condition in women with benign breast dysplasia

DOI
https://dx.doi.org/10.18565/aig.2026.307

Yureneva S.V., Yakushevskaya O.V., Anisimkova A.A.

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow, Russia

The importance of widespread breast cancer screening lies in the implementation of a two-stage strategy: the detection of background and pre-cancerous conditions, as well as the diagnosis of malignant neoplasms at the preclinical stage. Regular mammographic examination of women 40–75 years old with an interval of 1–2 years can reduce mortality from breast cancer by 25–35%. The assessment of breast cancer risk factors is fundamental for determining individual screening strategies and tailored management of women. Researchers and clinicians in the oncology community are primarily focused on developing and implementing strategies aimed at addressing modifiable risk factors for breast cancer, reducing incidence and mortality rates among cancer patients, and improving their survival rates. Each tumor has its own unique pathogenetic profile. The genome determines the key morphological characteristics and ‘behavioral’ features of tumors. However, despite the major importance of the ‘genetic basis’, epigenetic processes play an equally significant role in the development of neoplasms. In the context of breast disease, there is extensive discussion regarding the role of early epigenetic alterations in cells and, consequently, the potential for developing an oncoprotective approach in medicine.
This review presents the key strategies for secondary prevention of breast cancer based on mammography screening and the management of underlying benign breast conditions. The article provides a comparative assessment of national protocols for the management of patients, taking into account individual breast cancer risk, and outlines the efficacy profile and experience of using the medication indole-3-carbinol (Indinol Forto, ALCEA LLC, Russia), a compound known for its epigenetic mechanism of action. The search for relevant information was conducted in accordance with the stated topic using keywords to index articles in search engines and on the platforms PubMed, Google Scholar, ScienceDirect, CyberLeninka, and eLIBRARY.RU over the last 15 years.
Conclusion. Efforts to reduce the incidence of breast cancer must begin with the development of clear preventive medicine protocols, the essence of which lies in addressing modifiable risk factors for breast cancer (treating obesity, giving up harmful habits, optimizing physical activity, etc.), regular screening, early diagnosis and correction of morphofunctional changes in the breast that predispose to the development of a neoplastic process. Indinol Forto is registered as a non-hormonal medication with a proven effect on the structure of breast tissue. Preliminary data obtained during research into the efficacy/safety profile of the medication Indinol Forto®, which acts via an epigenetic mechanism, are opening up new horizons for preventive oncology.  

Authors’ contributions. Yureneva S.V., Yakushevskaya O.V., Anisimkova A.A. – developing the concept and design of the study, collecting and processing the material, writing the text, editing the article.
Conflicts of interest. The authors declare no conflicts of interest.
Funding. The work was carried out without financial support.  
Generative Artificial Intelligence. No generative artificial intelligence technologies were used in the preparation of this article.
For citation: Yureneva S.V., Yakushevskaya O.V., Anisimkova A.A. New trends in breast cancer screening. 
The effect of epigenetic therapy on breast tissue condition in women with benign breast dysplasia.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2026; (10): 136-145 (in Russian)
https://dx.doi.org/10.18565/aig.2026.307

Keywords

mastopathy
benign mammary dysplasia
fibrocystic disease
indinol
indolсarbinol
breast cancer
Full text (in Russian)

References

  1. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024; 74(3): 229-63. https://dx.doi.org/10.3322/caac.21834.
  2. Протасова А.Э., Вандеева Е.Н. Диффузные заболевания молочной железы: новый вектор таргетной терапии. Гинекология. 2017; 19(2): 42-9. [Protasova A.E., Vandeeva E.N. Diffusive breast diseases: a new vector of targeted therapy. Gynecology. 2017; 19(2): 42-9 (in Russian)].
  3. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Доброкачественная дисплазия молочной железы. 2024. Доступно по: https://cr.minzdrav.gov.ru/preview-cr/598_3 [Ministry of Health of the Russian Federation. Clinical guidelines. Benign breast dysplasia. 2024. Available at: https://cr.minzdrav.gov.ru/preview-cr/598_3 (in Russian)].
  4. Каприн А.Д., Рожкова Н.И., ред. Доброкачественные заболевания молочной железы. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа; 2026. 456 с. https://dx.doi.org/10.33029/9704-9732-6-DZM-2026-1-456 [Kaprin A.D., Rozhkova N.I., eds. Benign diseases of the mammary gland. 2nd ed., rev. and add. Moscow: GEOTAR-Media; 2026. 456 p. (in Russian). https://dx.doi.org/10.33029/9704-9732-6-DZM-2026-1-456].
  5. Geiger A.J., Hovey R.C. Development of the mammary glands and its regulation: how not all species are equal. Anim. Front. 2023; 13(3): 44-54. https://dx.doi.org/10.1093/af/vfad029
  6. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer and Screening and Diagnosis. Version 1.2026. March 5,2026. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1421
  7. WHO. Breast cancer: prevention and control. https://web.archive.org/web/20190520024053/https://www.who.int/cancer/detection/breastcancer/en/index1.html
  8. Кулагина Н.В., Одинцов В.А. Мастодиния: патогенез, диагностика, лечение. Акушерство и гинекология. 2022; 6: 33-9. https://dx.doi.org/10.18565/aig.2022.6.33-39 [Kulagina N.V., Odintsov V.A. Mastodynia: pathogenesis, diagnosis, and treatment. Obstetrics and Gynecology. 2022; (6): 33-9(in Russian). https://dx.doi.org/10.18565/aig.2022.6.33-39].
  9. Plu-Bureau G., Lê M.G., Sitruk-Ware R., Thalabard J.C. Cyclical mastalgia and breast cancer risk: results of a French cohort study. Cancer Epidemiol. Biomarkers Prev. 2006; 15(6): 1229-31. https://dx.doi.org/10.1158/1055-9965.EPI-05-0745
  10. Libesman S., Li T., Marinovich M.L., Seidler A.L., Tagliafico A.S., Houssami N. Interval breast cancer rates for tomosynthesis vs mammography population screening: a systematic review and meta-analysis of prospective studies. Eur Radiol. 2025; 35(3): 1478-89. https://dx.doi.org/10.1007/s00330-024-11085-9
  11. Heywang-Köbrunner S.H., Jänsch A., Hacker A., Weinand S., Vogelmann T. Digital breast tomosynthesis (DBT) plus synthesised two-dimensional mammography (s2D) in breast cancer screening is associated with higher cancer detection and lower recalls compared to digital mammography (DM) alone: results of a systematic review and meta-analysis. Eur. Radiol. 2022; 32(4):2301-12. https://dx.doi.org/10.1007/s00330-021-08308-8
  12. Houssami N., Zackrisson S., Blazek K., Hunter K., Bernardi D., Lang K. et al. Meta-analysis of prospective studies evaluating breast cancer detection and interval cancer rates for digital breast tomosynthesis versus mammography population Screening. European Journal of Cancer. 2021; 148(4): 14-23. https://dx.doi.org/10.1016/j.ejca.2021.01.035
  13. Screening for Breast Cancer. US Preventive Services Task Force Recommendation Statement. JAMA. 2024; 331(22): 1918-30. https://dx.doi.org/10.1001/jama.2024.5534
  14. American College of Obstetricians and Gynecologists. Age to Initiate Routine Breast Cancer Screening: ACOG Clinical Practice Update. Obstet. Gynecol. 2025; 145(1): e40-e44. https://dx.doi.org/10.1097/AOG.0000000000005757
  15. ACR Female Breast Cancer Screening revised 2025. Available at: https://www.acr.org/News-and-Publications/Media-Center/2023/ACR-SBI-Statement-on-New-USPSTF-Breast-Cancer-Screening-Recommendations
  16. Приказ Минздрава России от 27.04.2021 N 404н (ред. от 15.06.2026) «Об утверждении Порядка проведения профилактического медицинского осмотра и диспансеризации определенных групп взрослого населения» (Зарегистрировано в Минюсте России 30.06.2021 N 64042) (с изм. и доп., вступ. в силу с 01.09.2026). Доступно по: https://sudact.ru/law/prikaz-minzdrava-rossii-ot-27042021-n-404n/ [Order of the Ministry of Health of the Russian Federation No. 404n dated 27.04.2021 (ed. 15.06.2026) "On approval of the Procedure for conducting preventive medical examination and medical examination of certain groups of the adult population" (Registered with the Ministry of Justice of the Russian Federation 30.06.2021 No. 64042) (amend. and supplement., entry. by virtue of 01.09.2026). Available at: https://sudact.ru/law/prikaz-minzdrava-rossii-ot-27042021-n-404n/ (in Russian)].
  17. American College of Radiology. ACR Appropriateness Criteria®Female Breast Cancer Screening. 2025. Available at: https://acsearch.acr.org/docs/70910/narrative
  18. Monticciolo D.L., Newell M.S., Moy L., Niell B., Monsees B. Breast cancer screening in women at higher-than-average risk: Recommendations from the ACR. J. Am. Coll. Radiol. 2018; 15(3 Pt A): 408-14. https://dx.doi.org/10.1016/j.jacr.2017.11.034
  19. Seely J.M., Bissell M.B. BI-RADS v2025: A Welcome Update. AJR. 2026;226: 4. https://dx.doi.org/10.2214/AJR.26.34678
  20. Destounis S., Bennett D., Loving V.A., Strigel R., Leung J. The BI-RADS v2025 Manual: Key Updates for Everyday Practice—AJR Expert Panel Narrative Review. AJR. August 5, 2026. https://dx.doi.org/10.2214/AJR.26.35240
  21. Committee on Practice Bulletins-Gynecology. Practice Bulletin Nunber 179: Breast cancer risk assessment and screening in average-risk women. Obstet. Gynecol. 2017; 130: e1-e16. https://dx.doi.org/10.1097/AOG.0000000000002158
  22. U.S. Preventive Services Task Force. Breast Cancer: Screening. April 30, 2024. Available at: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening
  23. American Cancer Society. American Cancer Society Recomendations for the early detection of breast cancer. 2026. Available at: https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html
  24. Fuchsjäger M.H., Clauser P., Mann R.M. ESR Essentials: screening for breast cancer - general recommendations by EUSOBI. Eur. Radiol. 2024; 34(10): 6348-57. https://dx.doi.org/10.1007/s00330-024-10740-5
  25. Comparing Breast Cancer Screening Guidelines – Guidelines Side-By-Side (Breast Cancer Awareness Month). 2024. Available at: https://www.guidelinecentral.com/insights/breast-cancer-screening-side-by-side/
  26. U.S. Food & Drug Administration. Mammography Quality StandardsAct (MQSA) and MQSA Program. Available at: https://www.fda.gov/radiation-emitting-products/mammography-quality-standards-act-mqsa-and-mqsa-program
  27. Qaseem A., Harrod C.S., Balk E.M., Etxeandia-Ikobaltzeta I., Crandall C.J.; Clinical Guidelines Committee of the American College of Physicians. Screening for breast cancer in asymptomatic, average-risk adult females: A Guidance Statement from the American College of Physicians (Version 2). Ann. Intern. Med. 2026; 179(6): 842-56. https://dx.doi.org/10.7326/ANNALS-25-05116
  28. Pederson H.J. Breast cancer screening in midlife and beyond. Menopause. 2026; 1(33): 83. https://dx.doi.org/10.1097/GME.0000000000002701
  29. Власов А.В., Якушевская О.В. Химиопрофилактические свойства 3,3'-дииндолилметана: от экспериментального до клинического применения. Гинекология. 2024; 26(3): 270-4. https://dx.doi.org/10.26442/20795696.2024.3.202953 [Vlasov A.V., Yakushevskaya O.V. Chemopreventive properties of 3,3'-diindolylmethane: From experimental to clinical studies. A review. Gynecology. 2024; 26(3): 270-4 (in Russian). https://dx.doi.org/10.26442/20795696.2024.3.202953].
  30. Киселев В.И., Муйжнек Е.Л., Ашрафян Л.А., Сухих Г.Т. Эпигенетика в гинекологии и онкогинекологии: WIF и реальность. Акушерство и гинекология: новости, мнения, обучение. 2018; 1: 18-26. https://dx.doi.org/10.24411/2303-9698-2018-00002 [Kiselev V.I., Muyzhnek E.L., Ashrafyan L.A., Sukhikh G.T. Epigenetics in gynecology and oncogynecology: WIF and reality. Obstetrics and Gynecology: News, Opinions, Training. 2018; (1): 18-26 (in Russian). https://dx.doi.org/10.24411/2303-9698-2018-00002].
  31. Якушевская О.В., Юренева С.В., Протасова А.Э. Метаболизм эстрогенов: почему так важно сохранять равновесие? Гинекология. 2019; 21(6): 31-5. https://dx.doi.org/10.26442/20795696.2019.6.190752 [Yakushevskaya O.V., Yureneva S.V., Protasova A.E. Estrogen metabolism: why it's so crucial to keep the balance? Gynecology. 2019; 21(6): 31-5 (in Russian). https://dx.doi.org/10.26442/20795696.2019.6.190752].
  32. Беспалов В.Г., Негусторов Ю.Ф. Маммографическая плотность как критерий эффективности лечения мастопатии и снижения риска рака молочной железы. Опухоли женской репродуктивной системы. 2017; 13(2): 33-41. https://dx.doi.org/10.17650/1994-4098-2017-13-2-33-41 [Bespalov V.G., Negustorov Yu.F. Mammographic density as a criterion of the efficiency of treatment of benign breast disease and reducing risk of breast cancer. Tumors of female reproductive system. 2017; 13(2): 33-41 (in Russian).https://dx.doi.org/10.17650/1994-4098-2017-13-2-33-41].
  33. Меских Е.В., Ашрафян Л.А. Оценка эффективности инструментальной диагностика боли и патогенетической терапии больных с доброкачественной дисплазией молочных желез. Акушерство и гинекология. 2025; 4: 146-56. https://dx.doi.org/10.18565/aig.2025.103 [Meskikh E.V., Ashrafyan L.A. Assessing the effectiveness of instrumental diagnostics and pathogenetic therapy in patients with benign breast dysplasia. Obstetrics and Gynecology. 2025; (4): 146-56 (in Russian). https://dx.doi.org/10.18565/aig.2025.103].
  34. Бурдина И.И., Запирова С.Б., Рожкова Н.И., Лабазанова П.Г., Мазо М.Л., Прокопенко С.П., Долгушин С.Ю. Результаты лечения масталгии у женщин различного возраста препаратом на основе индолкарбинола. Акушерство и гинекология. 2026; 1: 90-6. https://dx.doi.org/10.18565/aig.2025.369 [Burdina I.I., Zapirova S.B., Rozhkova N.I., Labazanova P.G., Mazo M.L., Prokopenko S.P., Mikushin S.Yu. Results of treatment of mastalgia in women of different ages with indolcarbinol. Obstetrics and Gynecology. 2026; (1): 90-6 (in Russian). https://dx.doi.org/10.18565/aig.2025.369].
  35. Плащинская А.М., Красенков Ю.В., Михельсон А.Ф., Лебеденко Е.Ю., Феоктистова Т.Е. Комплексный подход к лечению доброкачественных заболеваний молочных желез. РМЖ. Мать и дитя. 2018; 26(5(I)): 20-2. [Plashchinskaya A.M., Krasenkov Yu.V., Mikhelson A.F., Lebedenko E.Yu., Feoktistova T.E. An integrated approach to the treatment of benign breast diseases. RMJ. 2018; 26(5(I): 20-2 (in Russian)].
  36. Плащинская А.М., Михельсон А.Ф., Лебеденко Е.Ю., Ермолова Н.В. Комплексный подход к лечению доброкачественных заболеваний молочных желез у пациенток с избыточной массой тела. Акушерство и гинекология. 2019; 8: 165-9. https://dx.doi.org/10.18565/aig.2019.8.165-169 [Plashchinskaya: A.M., Mikhelson A.F., Lebedenko E.Yu., Ermolova N.V. A comprehensive approach to treating benign breast diseases in overweight patients. Obstetrics and Gynecology. 2019; (8): 165-9 (in Russian). https://dx.doi.org/10.18565/aig.2019.8.165-169].
  37. Ашрафян Л.А., Бабаева Н.А., Антонова И.Б., Алешикова О.И., Герфанова Е.В. Значение эстрогенных метаболитов в канцерогенезе опухолей женской репродуктивной системы. Медицинский оппонент. 2019; 3(7): 34-9. [Ashrafyan L.A., Babaeva N.A., Antonova I.B., Aleshikova O.I., Gerfanova E.V. The role of hormonal disbalance in the carcinogenesis of tumors of the female reproductive system. Medical Opponent. 2019; 3(7): 34-9.(in Russian)].
  38. Сметник А.А., Сметник В.П., Киселев В.И. Опыт применения индол-3-карбинола в лечении заболеваний молочной железы и профилактике рака молочной железы. Акушерство и гинекология. 2017; 2: 106-12.https://dx.doi.org/10.18565/aig.2017.2.106-12 [ Smetnik A.A., Smetnik V.P., Kiselev V.I. Experience with indole-3-carbinol used to treat diseases of the breast and to prevent breast cancer. Obstetrics and Gynecology. 2017; (2): 106-12(in Russian). http://dx.doi.org/10.18565/aig.2017.2.106-12].

Received 11.09.2026

Accepted 21.10.2026

About the Authors

Svetlana V. Yureneva, Dr. Med. Sci., Professor, Deputy Director for Science of the Institute of Oncogynecology and Mammology, Professor at the Department of Obstetrics and Gynecology at the Institute of Professional Education, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology,
Ministry of Health of Russia, 117997, Russia, Moscow, Ac. Oparin str., 4, +7(916)179-74-00, syureneva@gmail.com, https://orcid.org/0000-0003-2864-066Х
Oksana V. Yakushevskaya, PhD, Researcher at the Scientific and Consultative Diagnostic Department of Outpatient Oncological Care, Academician V.I. Kulakov National Medical Research Center for Obsterics, Gynecology and Perinatology, Ministry of Health of Russia, 117997, Russia, Moscow, Ac. Oparina str., 4, +7(905)534-72-08, aluckyone777@gmail.com, https://orcid.org/0000-0002-7430-1207
Alla A. Anisimkova, radiologist at the Department of Radiation Diagnostics, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation, +7(931)204-26-01, alla/anisimkova@yandex.ru, https://orcid.org/0009-0002-8709-139X

Similar Articles

№10 / 2023
Bakhova L.A., Shevlyukova T.P., Keln A.A., Shvedsky M.S., Mateykovich E.A., Nekrasova O.V., Shkuratova V.V., Karmaeva O.S.
BRCA-associated breast cancer during pregnancy
№3 / 2023
Apolikhina I.A., Prilepskaya V.N., Gorbunova E.A., Mezhevitinova E.A., Bychkova A.E.
Estetrol – a new stage of combined hormonal contraception
№10 / 2020
Maltseva L.I., Garifullova Yu.V., Yupatov Е.Yu.
Use of vitamin D to maintain women’s reproductive health: realities and prospects
№2 / 2023
Kravchenko E.N., Naboka M.V.
Treatment for diffuse benign breast diseases
№11 / 2022
Yakushevskaya O.V., Yureneva S.V., Ashrafyan L.A., Babaeva N.A.
Contraception in cancer survivors: Breast and gynecological cancers (Part I)

Site is using cookie

By continuing, you consent to the processing of cookies that ensure the proper functioning of the site.